CClinicalTrials.gg
CompletedNCT05866042PSYCHOBOOSTUpdated May 19, 2023

Boosting Psychotherapy Effects by Means of Transcranial Direct Current Stimulation

An interventional study of tDCS in Major Depressive Disorder, sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico. Completed at 1 site in Italy. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-05-19.

Sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years after the study started (first participant enrolled May 2021, registered May 2023).
Phase
Not applicable
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The present study involves the administration of three types of interventions in patients with depressive episode in the context of DDM. Two-thirds of the patients will carry out a course of excitatory tDCS sessions on the left DLPFC, so as to improve attention regulation on information characterized by negative emotions and have an antidepressant effect, simultaneously with the performance of a task, the attentional training technique (ATT), aimed at achieve effective management of emotions characterized by negative emotions and which constitutes a fundamental exercise of MCT. In half of the patients who will undergo tDCS treatment, after each session of stimulation, an MCT session will be carried out. In addition, before and after the cycle of tDCS sessions and MCT sessions will be explored, in a subgroup of patients, in the context of a pilot study, the TMS- EEG of the change in depressive symptomatology, which can be correlated with the different proposed therapeutic interventions.

Read the detailed description

The study - interventional, nonpharmacological, using medical devices, nonprofit - is aimed at evaluating the potential effectiveness of a multimodal intervention for the treatment of unipolar depression. The intervention involves the use of a neuro-stimulation technique, the Transcranial Direct Current Stimulation (transcranial Direct Current Stimulation - tDCS), combined with a psychotherapy intervention, metacognitive therapy (MetaCognitive Therapy, MCT). TDCS is a noninvasive neurostimulation technique involving the transcranial application of a low-amperage electric current at a region of the cerebral cortex involved in the pathogenesis of major depression, the dorsolateral prefrontal cortex. It has been demonstrated how such stimulation has a neuromodulating effect on synaptic plasticity, with efficacy in unipolar major depression. The technique also has a good safety, as it is not associated with major side effects. MCT is based on the metacognitive model, according to which psychopathological processes are consequent to a cognitive style characterized by repetitive forms of thinking (such as rumination) and maladaptive behaviors such as avoidance and thought suppression. The MCT, through attention training techniques, detached mindfulness and behavioral interventions on metacognitions, has shown effectiveness in major depressive disorder comparable to that of psychotherapeutic interventions considered, within psychotherapies, to be first-line such as cognitive-behavioral therapy. The experimental design will be that of a randomized, double-blind study with three arms of treatment, each consisting of 8 sessions, involving the administration of 1) the neurostimulation intervention (tDCS), 2) of the psychotherapeutic intervention alone (MCT), 3) of both techniques in consecution (tDCS-MCT). This design is aimed at evaluating a potential additive/synergistic effect of the two interventions when combined. During the tDCS sessions, each lasting 20 minutes, the patient will apply the technique of attention training, aimed at further activating the region stimulated by neurostimulation, so as to so as to amplify the plasticity stimulated by tDCS, achieving a synergistic effect. To follow, a 40-minute MCT session will be carried out. The effectiveness of these interventions will be assessed by heteroadministered and self-administered at time zero, after treatment, at two follow-ups of 6 and 12 months. Before and after the treatment cycle (tDCS sessions and MCT sessions), a subgroup of patients will be explored, in the context of a pilot study, the TMS-EEG correlates of the change in symptomatology depression, which can be correlated with the different proposed therapeutic interventions.

02

Conditions studied

  • Major Depressive Disorder
03

In context

Depressive Disorder

4,845 studies on the registry are indexed under Depressive Disorder; 514 are open to participants now.

This study's enrollment of 54 is below the median of 80 across 3,999 interventional studies indexed under Depressive Disorder.

Browse Depressive Disorder studies →

Lead sponsor

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico is the lead sponsor of 214 studies on the registry; 71 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Ability to provide informed consent to study
  • Ability to understand and speak the Italian language
  • DSM-5 diagnosis of Major Depressive Disorder.
  • Ongoing depressive episode of at least moderate intensity (HAM-D> 18)

Exclusion criteria

Exclusion Criteria:

  • Previous tDCS sessions with significant side effects
  • Positive personal history for seizures
  • Positive family history for epileptic disease
  • Positive personal history for neurological disease
  • Positive personal history for head trauma with loss of consciousness
  • Positive personal history for frequent and severe headaches
  • Positive personal history for neurosurgical procedures
  • Prior implantation of neurostimulation implants (DBS, VNS, etc.)
  • Prior implantation of defibrillator or pace-maker
  • Possibility of pregnancy or established pregnancy
  • Substance or alcohol abuse in the past 6 months
  • Positive personal history for schizophrenia or schizoaffective disorder
  • Positive personal history of intellectual disability ("mental retardation")
  • Current hospitalization
  • Cardiac, respiratory, renal, hepatic failure, immunosuppression status
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Active tDCS

    Administration of active tDCS, not followed by MCT session, but by a usual visit psychiatric follow-up

    Device: tDCS

  • No intervention
    sham tDCS and MCT

    Administration of sham tDCS, followed by MCT session

  • Experimental
    active tDCS and MCT

    Administration of active tDCS, followed by MCT session

    Device: tDCS

Interventions

  • DevicetDCS

    TDCS is a noninvasive neurostimulation technique involving the transcranial application of a low-amperage electric current at a region of the cerebral cortex involved in the pathogenesis of major depression, the dorsolateral prefrontal cortex. In healthy subjects, the administration of excitatory tDCS on the left DLPFC improves the regulation of attention on information characterized by negative emotions, as does the administration of inhibitory tDCS on the DLPFC Right tDCS produces small changes in the neuronal membrane potential, thus increasing or decreasing the excitability of the stimulated tissue. Simultaneous administration to behavioral tasks designed to activate the stimulated cortical region should achieve a synergistic, amplifying the plasticity stimulated by the task.

06

What researchers measure

Primary outcomes

  1. to evaluate the potential superiority, from the point of view of therapeutic efficacy in depression, of the approach of combined administration of tDCS and MCT, compared with interventions based tDCS alone or MCT alone.

    Change in the Hamilton Depression Rating Scale will be used as parameters, during follow-up (end of treatment, 1, 3, 6 and 12 months).

    Time frame: end of treatment, 1, 3, 6 and 12 months

Secondary outcomes

  1. To evaluate the TMS-EEG correlates of change in depressive symptomatology, correlating them with the different proposed therapeutic interventions, in a subgroup of patients recruited, in the context of a pilot study.

    Change, at the end of treatment, in TMS-EEG connectivity measures, in a subgroup of patients recruited 2. Change, during follow-up (end of treatment, 1, 3, 6 and 12 months), in the scores of the following scales: * Beck Depression Inventory * SCL-90 Remorse Rating Scales: * Penn State Worry Questionnaire * Metacognition Questionnaire-30 * Ruminative Response Scale * Anger rumination scale Neuropsychological tests * Digit span forward and backward * Phonemic and semantic verbal fluency

    Time frame: 12 months

07

Study locations

1 site
  • Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico
    Milan, MI 20100, Italy
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05866042
Lead sponsor
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Responsible party
Sponsor
First posted
May 19, 2023
Start date
May 1, 2021
Primary completion
Apr 30, 2022
Completion
Apr 30, 2023
Last update
May 19, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion